PHIN 1314
Alternative Names: PHIN-1314Latest Information Update: 24 Apr 2023
At a glance
- Originator PharmaIN
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Fibrosis; Inflammation; Solid tumours
Highest Development Phases
- Preclinical Fibrosis; Inflammation; Solid tumours
Most Recent Events
- 07 Apr 2023 PHIN 1314 is available for licensing and collaboration as of 07 Apr 2023. https://pharmain.com/ (PharmaIN pipeline, April 2023)
- 07 Apr 2023 Preclinical trials in Fibrosis in USA (SC), prior in 2022 (PharmaIN pipeline, April 2023)
- 07 Apr 2023 Preclinical trials in Inflammation in USA (SC), prior in 2022 (PharmaIN pipeline, April 2023)